A5011817630- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- MicroRNA in disease regulation
- Neuroendocrine Tumor Research Advances
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Intraperitoneal and Appendiceal Malignancies
- RNA modifications and cancer
- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Nuclear Structure and Function
- Circular RNAs in diseases
- Cancer Cells and Metastasis
- Biochemical and Molecular Research
- Colorectal and Anal Carcinomas
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Research and Treatments
- Epigenetics and DNA Methylation
- Neuroblastoma Research and Treatments
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- Cancer, Hypoxia, and Metabolism
Wayne State University
2016-2025
The Barbara Ann Karmanos Cancer Institute
2016-2025
Henry Ford Health System
2022-2025
Henry Ford Hospital
2023-2025
SWOG Cancer Research Network
2007-2025
Cancer Research Center
2003-2020
West Virginia University
2020
Yerevan State Medical University
2020
Webber International University
2019
University of Detroit Mercy
2019
Brivanib is a dual inhibitor of vascular-endothelial growth factor and fibroblast receptors that are implicated in the pathogenesis hepatocellular carcinoma (HCC). Our multinational, randomized, double-blind, phase III trial compared brivanib with sorafenib as first-line treatment for HCC.Advanced HCC patients who had no prior systemic therapy were randomly assigned (ratio, 1:1) to receive 400 mg twice daily orally (n = 578) or 800 once 577). Primary end point was overall survival (OS)....
Abstract Pancreatic cancer is the fourth most common cause of death in United States, and aggressiveness pancreatic part due to its intrinsic extrinsic drug resistance characteristics, which are also associated with acquisition epithelial-to-mesenchymal transition (EMT). Emerging evidence suggests that processes EMT regulated by expression status many microRNAs (miRNA), believed function as key regulators various biological pathologic during tumor development progression. In present study,...
Purpose Patients with advanced pancreas cancer present disease that is poorly responsive to conventional therapies. Preclinical and early clinical evidence has supported targeting the epidermal growth factor receptor (EGFR) signaling pathway in patients cancer. This trial was conducted evaluate contribution of an EGFR-targeted agent standard gemcitabine therapy. Cetuximab a monoclonal antibody against ligand-binding domain receptor. Methods unresectable locally or metastatic pancreatic...
Purpose No standard treatment exists for patients with cholangiocarcinoma whom first-line gemcitabine-based therapy fails. Fibroblast growth factor receptor 2 ( FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas. BGJ398, an orally bioavailable, selective pan-FGFR kinase inhibitor, has shown preliminary clinical activity against tumors FGFR alterations. Methods A multicenter, open-label, phase II study ClinicalTrials.gov identifier: NCT02150967)...
Purpose Epidermal growth factor receptor/human epidermal receptor 1 (EGFR/HER1) and ligand expression is frequently seen in hepatocellular cancers (HCCs). Erlotinib (Tarceva, OSI-774; OSI Pharmaceuticals, Melville, NY) a tyrosine kinase inhibitor with specificity for the EGFR/HER1. Methods The primary objective of this study was to determine proportion patients advanced HCC who were progression-free at 6 months. Patients either unresectable or metastatic disease studied. Only one prior...
Curcumin induces cancer cell growth arrest and apoptosis in vitro, but its poor bioavailability vivo limits antitumor efficacy. We have previously evaluated the of novel analogues curcumin compared with curcumin, we found that analogue CDF exhibited greater systemic pancreatic tissue bioavailability. In this study, effects or alone combination gemcitabine on viability gemcitabine-sensitive gemcitabine-resistant (PC) lines. Mechanistic investigations revealed a significant reduction...
The aggressive course of pancreatic cancer is believed to reflect its unusually invasive and metastatic nature, which associated with epidermal growth factor receptor (EGFR) overexpression NF-kappaB activation. MicroRNAs (miRNA) have been implicated in the regulation various pathobiological processes cancer, including metastasis other human malignancies. In this study, we report lower expression miR-146a cells compared normal duct epithelial cells. Reexpression inhibited capacity concomitant...
Abstract Cancer chemotherapeutic strategies commonly require multiple agents. However, use of agents contributes to added toxicity resulting in poor treatment outcome. Thus, combination chemotherapy must be optimized increase tumor response and at the same time lower its toxicity. Chemotherapeutic are known induce nuclear factor κB (NF-κB) activity cells, cell killing drug resistance. In contrast, genistein has been shown inhibit NF-κB growth various cancer cells without causing systemic We...
mutations are rarely associated with objective responses to the BRAF inhibitor vemurafenib in patients metastatic colorectal cancer (CRC). Blockade of
Pegylated recombinant human hyaluronidase (PEGPH20) degrades hyaluronan (HA) and, in combination with chemotherapy, prolongs survival preclinical models. The activity of PEGPH20 modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) was evaluated patients metastatic pancreatic cancer (mPC).
Purpose Biliary cancers overexpress epidermal growth factor receptor (EGFR), and angiogenesis has been correlated with poor outcome. Erlotinib, an EGFR tyrosine kinase inhibitor, bevacizumab, a vascular endothelial (VEGF) inhibitor have each shown to activity in biliary cancer. The primary objective of this study was evaluate the response rate by Response Evaluation Criteria Solid Tumors (RECIST). Secondary end points included overall survival (OS), time progression (TTP), VEGF levels,...
PURPOSE The aim of this work was to provide an update the ASCO guideline on metastatic pancreatic cancer pertaining recommendations for therapy options after first-line treatment. METHODS convened Expert Panel and conducted a systematic review second-line cancer. RESULTS One randomized controlled trial olaparib versus placebo, one report phase I II studies larotrectinib, entrectinib met inclusion criteria inform update. RECOMMENDATIONS New or updated germline somatic testing microsatellite...
Clinical outcomes after curative treatment of resectable pancreatic ductal adenocarcinoma (PDA) remain suboptimal. To assess the potential early control systemic disease with multiagent perioperative chemotherapy, we conducted a prospective trial.
The efficacy of immunotherapy varies widely among different gastrointestinal cancers. Response to immune checkpoint inhibitors is shown correlate with tumor mutation load (TML), mismatch repair deficiency (dMMR) status, and programmed cell death-ligand 1 (PD-L1) expression. Herein, we quantify TML, dMMR, PD-L1 expression determine their interrelationship in Here, a total 4,125 tumors from 14 cancer sites were studied using validated assays. Next-generation sequencing was performed on genomic...
Objective: The optimal neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods: S1505 (NCT02562716) was a randomized phase II study of perioperative chemotherapy with mFOLFIRINOX (Arm 1) or gemcitabine/nab-paclitaxel 2). Measured parameters included resection rate, margin positivity, pathologic response, toxicity. Results: Between 2015 2018, 147 patients were randomized. Of these, 44 (30%) deemed ineligible (43 by...
Tumor sidedness has emerged as an important prognostic and predictive factor in the treatment of colorectal cancer. Recent studies demonstrate that patients with advanced right-sided colon cancers have a worse prognosis than those left-sided or rectal cancers, these patient subgroups respond differently to biological therapies. Historically, management metastatic been similar, cancer grouped together large clinical trials. Clearly, differences molecular biology among colon, should be further...
Abstract Background Gastroesophageal cancers are often grouped together even though that originate in the esophagus exhibit different histological features, geographical distribution, risk factors, and clinical characteristics than those originating stomach. Herein, we aimed to compare molecular of three gastroesophageal cancer types: esophageal squamous cell carcinoma (ESCC), adenocarcinoma (EAC), gastric (GAC). Subjects, Materials, Methods In total, 3,342 were examined. Next-generation...
KRAS mutation (MT) is a major oncogenic driver in pancreatic ductal adenocarcinoma (PDAC). A small subset of PDACs harbor wild-type (WT). We aim to characterize the molecular profiles WT PDAC uncover new pathogenic drivers and offer targeted treatments.
Epidermal growth factor receptor/human epidermal receptor 1 and ligand expression is common in biliary cancers (BILI) may be associated with worse outcome. The primary objective of this study was to determine the proportion patients advanced BILI who were progression-free at 6 months.Patients either unresectable or metastatic disease studied. Only one prior systemic locoregional therapy allowed. Erlotinib administered continuously a dose 150 mg per day orally.Forty-two enrolled. median age...